Maravai LifeSciences Acquires TriLink BioTechnologies
Maravai LifeSciences, a transformative company in the life science research market, announced today that it has acquired TriLink BioTechnologies, leaders in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics. The acquisition fits with Maravai LifeSciences’ goal of creating a market-leading life science business by bringing investment, strong and experienced leadership, processes and best practices to companies with notable growth potential.
"We are investing in companies like TriLink BioTechnologies that have high-quality products, a history of success and outstanding growth possibilities,” explains David Weber, vice president and chief commercial officer for Maravai LifeSciences. We have a strong management team with extensive experience in the life science tools market, which we bring to the companies we acquire."
About Maravai LifeSciences
Maravai LifeSciences is committed to catalyzing the growth of successful, entrepreneurial, life science companies by providing expertise, capital, processes and systems. Maravai LifeSciences companies provide tools and services to pharmaceutical and biopharmaceutical research and development companies to enable breakthrough discoveries and improvements in human well-being. The Maravai LifeSciences portfolio includes Vector Laboratories, TriLink BioTechnologies, Cygnus Technologies and Glen Research. Maravai LifeSciences is a portfolio company of GTCR, a leading private equity firm focused on investing in growth companies in financial services, technology and information services, and healthcare.
About TriLink BioTechnologies
Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of high-quality nucleic acid and mRNA products for research, diagnostics, therapeutics and OEM customers. TriLink BioTechnologies’ products are instrumental in the discovery and development processes in gene and oligonucleotide therapy, nucleoside chemotherapy and diagnostics. The company is ISO 9001 certified and is compliant with ICH Q7, 21 CFR 210 and 21 CFR 820. TriLink BioTechnologies is headquartered in San Diego, Calif., where it also maintains its manufacturing facilities.
Contacts for the media:
David Weber, Chief Commercial Officer